DiscoverNeurology Today in 5Advances in cell therapies for Parkinson's, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
Advances in cell therapies for Parkinson's, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs

Advances in cell therapies for Parkinson's, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs

Update: 2025-05-15
Share

Description

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson's, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny. 

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Advances in cell therapies for Parkinson's, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs

Advances in cell therapies for Parkinson's, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs

American Academy of Neurology